SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced today that it has granted a request from the Department of Health and Human Services (HHS) that the Company extend through November 30, 2006 its offer submitted under Request for Proposal (RFP) No. DHHS-ORDC-DDA-05-12 entitled “Medical Countermeasures to Mitigate or Treat Neutropenia Alone or in Combination with Co-Morbidities Associated with Acute Radiation Syndrome (ARS).” While HHS has not provided Hollis-Eden with a new estimated contract award date, based on this extension an award could be made under this RFP at any time prior to the end of November 2006. As previously announced, Hollis-Eden was informed by HHS in June that the Company “is within the competitive range for discussion and further evaluation” on a potential procurement of its lead drug candidate, NEUMUNE™ (HE2100), under this RFP. Since that time, Hollis-Eden has been in ongoing discussions with HHS with respect to this potential procurement.
